Core Viewpoint - The newly released "Measures to Support the High-Quality Development of Innovative Drugs" aims to enhance the entire chain of innovative drug research, access, payment, and clinical application to better meet the diverse medication needs of the public [1][3]. Group 1: Policy Framework - The "Measures" outlines 16 specific initiatives across five major areas to establish a policy support system for the entire lifecycle of innovative drugs [3]. - A significant highlight is the establishment of a "Commercial Health Insurance Innovative Drug Directory," which allows companies to independently apply for inclusion in either the medical insurance or commercial insurance directory, or both [3]. Group 2: Access and Usage - The "Measures" address the issue of difficult access to innovative drugs by prohibiting medical institutions from using "drug proportion" or "product specification quantity limits" to affect the allocation of drugs [3]. - Medical institutions are encouraged to enhance their clinical usage capabilities for innovative drugs, allowing for "special case discussions" for reasonable use of drugs within the medical insurance directory [3]. Group 3: Global Competitiveness - To improve the global competitiveness of Chinese innovative drugs, the "Measures" propose three initiatives: building platforms to expand overseas markets, encouraging commercial insurance to invest in innovative drugs, and implementing price confidentiality mechanisms for drugs in the commercial insurance directory [4].